1 / 56

ERCP: A Potential Cause and a Potential Cure of Pancreatitis

ERCP: A Potential Cause and a Potential Cure of Pancreatitis. Grace H. Elta, MD Professor of Medicine Division of Gastroenterology University of Michigan. Complications of ERCP. General Considerations: Is the indication for ERCP strong enough to warrant the risks?

Download Presentation

ERCP: A Potential Cause and a Potential Cure of Pancreatitis

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. ERCP: A Potential Cause and a Potential Cure of Pancreatitis Grace H. Elta, MDProfessor of MedicineDivision of GastroenterologyUniversity of Michigan

  2. Complications of ERCP General Considerations: • Is the indication for ERCP strong enough to warrant the risks? • Low suspicion: Alternative imaging • Death in 0.4 -0.6% • Does the performing physician have adequate case volume?

  3. *P <0.05 * Overall Severe * 2.3 0.9 * Case Volume of Endoscopist

  4. ERCP Complications • Pancreatitis: 6.7%* • Perforation: 0.3% • Cholangitis: <1% • Cardiopulmonary / sedation: <1% • Failed procedure *Freeman ML et al GIE 2001

  5. Causes of Post-ERCP Pain • Pancreatitis • Transient Pain • Cholangitis • Perforation

  6. Post-ERCP Pain: What does it mean? • Pain at 2 hrs post-ERCP*: • 2/3 of pts developed pancreatitis • 1/3 of pts who did not get pancreatitis • Recovery room pain not very specific • 33% of panc. presents >4hrs post-ERCP** • Admission required in 12% with >1 risk factor and 4% without any *Gottlieb GIE 1996 **Freeman NEJM 1996

  7. Post-ERCP Pancreatitis • Definition requires all 3: • New or worsened pain • amylase 3X ULN > 24 hrs post-ERCP • requiring >2 days hospitalization • Severity: • Mild: <4 days hospitalization • Moderate: 4-10 d. hospitalization • Severe: >10 d. hospitalization

  8. Risk Factors for Post-ERCP Pancreatitis

  9. Risk Factors for Post-ERCP Pancreatitis

  10. Risks for Pancreatitis: Prospective US Multi-Center Study* Multivariate risk factorsOdds Ratio Minor sphincterotomy 3.8 Suspected SOD 2.6 Prior ERCP-pancreatitis 2.0 Age <60 1.6 2 or more pancreatic injections 1.5 Trainee involvement 1.5 Not risk factors: female gender, idiopathic pancreatitis, difficult cannulation, major sphincterotomy, SOM *Cheng AJG 2006

  11. Does SOM Increase Procedure-Induced Pancreatitis? • Suspected SOD pts: • ERCP with SOM vs. ERCP alone—No differences in pancreatitis rates (26%)* • Compared to 3% rate in bile duct stone pts • Pancreatitis risk increased by ES and pancreatography Conclusion: It’s the diagnosis (suspected SOD) not the manometry that increases risk *Singh GIE 2004

  12. Medications to Lower Post-ERCP Pancreatitis *4 positive / 1 negative studies **Single positive study

  13. NSAID Meta-analysis • 4 RCTs: 879 patients* • Diclofenac / indomethacin vs. placebo • Relative risk of pancreatitis: 0.35 • 65% decrease in pancreatitis, 90% decrease in severe pancreatitis • NNT to prevent one episode: 15 *Elmunzer Gut 2008

  14. Techniques to Lower Post-ERCP Pancreatitis • Wire cannulation instead of contrast* • Temporary PD stenting • Not clearly shown to be helpful: • Post-biliary ES botox • Pure cut cautery may be safer than blended cut • Low osmolality contrast * Lella GIE 2004

  15. Temporary Pancreatic Stenting • RCT: Stent lowers risk in biliary SOD pts* • Used for other high risk cases • Single pigtail flangeless 3F stents appear safer and more effective** • Spontaneous stent passage: 70-85% • Successful placement in 4 studies=88% *Tarnarsky Gastroenterology 1998 ** Rashdan Clin Gastro & Hep 2004

  16. Stenting to Minimize PancreatitisMeta-Analysis Singh P. GIE 2004;60:544.

  17. Problems with Prophylactic PD Stent • Technical difficulty in placement • Small stents require 0.018 guide wire • Increased risk in failed stent placement • May require repeat endoscopy • Increased cost • Possible stent-induced damage • Lack of expert agreement on methods

  18. Survey on PD Stents: Who should get one? Which one? • Agreed upon indications: • SOD • Pancreatic sphincterotomy (minor & major) • Ampullectomy • Indications according to some: • Pre-cut sphincterotomy (71%) • Prior post-ERCP pancreatitis (64%) • Suspected SOD / normal or no manometry (60%) • Traumatic or difficult cannulation (44%) • No agreement on stent size and length, how long stents left, and retrieval methods *Brackbill GIE 2006

  19. Post-ERCP Pancreatitis: Conclusions • Most common complication, 1/3 pts. take > 4hrs to present • Patient-related and technique-related risk factors are major determinants of risk • Limit pancreatic injection / wire for cannulation • Temporary PD stenting for high risk pts

  20. Endotherapy for the Pancreas • Indications: • Acute idiopathic pancreatitis • Chronic pancreatitis pain

  21. Idiopathic Acute Pancreatitis:Possible Etiologies • Microlithiasis / missed stones in GB / ducts • Pancreas divisum • Sphincter of Oddi dysfunction • Neoplasms • Subtle chronic pancreatitis • Autoimmune / genetic pancreatitis • Missed diagnosis of hypertriglyceridemia or hypercalcemia

  22. Idiopathic Pancreatitis:Possible Additional Labs • Cystic fibrosis genotype • Positive in 20% (range: 4-37%) • CA19-9 in suspected cancer • ANA and IGG4 subtype • Ionized serum calcium / parathormone • FH: trypsinogen gene and Spink1 • Repeat non-fasting triglyceride

  23. Idiopathic Pancreatitis: Diagnostic Choices • Diagnostic Choices • Wait for second episode • EUS • MRCP +/- secretin stimulation • ERCP with manometry • Empiric cholecystectomy • Factors affecting choice • Age= >40 years: 21% had neoplasm* • Absent gallbladder *Choudhari AJG 1998

  24. What is the role of Microlithiasis? • Microlithiasis: small (1-2 mm) stones • Sludge: Collection of crystals, mucin, glycoproteins, and cellular debris • Sludge may contain microlithiasis: terms used interchangeably clinically

  25. Microlithiasis in IAP: Gallbladder in Situ • High incidence (60-80%) centers of IAP due to microlithiasis • Low incidence (6-8%) centers Evaluation/Rx options: • Empiric cholecystectomy / trial of Urso • Bile crystal analysis: sensitivity 66% • EUS: Superior to crystal analysis* *Dahan Gut 1996

  26. Does Microlithiasis cause IAP Post Cholecystectomy? • Bile crystals rare in biliary SOD* • No biliary crystals in IAP pts** Conclusion: Bile duct Stones / microlithiasis are very rare cause of IAP post-cholecystectomy, best diagnosed by EUS*** *Quallich GIE 2001 **Law GIE 2002 ***Scheiman AJG 2001

  27. Acute Idiopathic Pancreatitis Diagnostic Tests • EUS • Accurate for P. divisum, tumors, bile duct or gallbladder stones • Pro: Safe Con: Not therapeutic, miss SOD • MRCP • Accurate for P. divisum, variable accuracy for tumors and missed stones, miss SOD • + Secretin: Improve image quality but value of P. duct dilation / flow is controversial

  28. Diagnostic Yield of EUS in IAP *Yusoff GIE 2004

  29. Chronic Pancreatitis Presenting as IAP • “Small duct” or minimal change • Difficult diagnosis • EUS: need > 5 criteria for certainty • Panc func tests: Also has accuracy issues • Treatment options: • Medical therapy first • ? Value to endoscopic therapy • Surgery relegated to resection

  30. EUS Diagnostic Accuracy in Chronic Pancreatitis • Number of EUS criteria only weakly correlated with fibrosis score* • >3 criteria: 80% sensitive & specific • EUS true cut and FNA also have poor specificity (65%) • Only moderate interobserver agreement on individual criteria** *Chong GIE 2007 **Wallace GIE 2001

  31. EUS in IAP Patient

  32. Endotherapy for P. Divisum

  33. Pancreas Divisum Treatment • Pancreas divisum as cause of IRP • Rx outcome: 127 pts in 8 series81% no further episodes in mean f/u of 27 mo • Long term (61 mos) f/u of 28 IRP pts* • 23 cured, 5 better, 3 repeated ERCP • NK vs traction sphincterotome?** • Restenosis rate: 13% NK vs 25% TS *Alsolaiman T1528 GIE 04 **Berkes T1532 GIE 04

  34. Acute pancreatitis can be a neoplastic presentation • Ampullary neoplasm • Ductal cancer / isolated MPD stricture • IPMN • Islet cell / metastatic cancer

  35. Ampullary Neoplasm

  36. Pancreatic Duct Stricture

  37. EUS of Case: Early Pancreatic Cancer

  38. Intraductal Papillary Mucinous Neoplasm: IPMN

  39. SO Anatomy

  40. Does SOD cause Idiopathic Acute Pancreatitis? Pro: • Present in 30-60% of IAP pts • Pts with panc. SOD more likely to get post-ERCP pancreatitis than those with normal SOM (26% vs. 7%)* • 60-80% IAP pts improve after sphincter ablation *Tarnasky Gastroenterology 1998

  41. Does SOD cause Idiopathic Acute Pancreatitis? Pro: • Present in 30-60% of IAP pts • Pts with panc. SOD more likely to get post-ERCP pancreatitis than those with normal SOM (26% vs. 7%)* • 60-80% IAP pts improve after sphincter ablation *Tarnasky Gastroenterology 1998

  42. Contemporary* Classification for Suspected Pancreatic SOD Type I -Pancreatic type pain -Amylase/lipase elevation -Dilated Pancreatic duct Type II -Pancreatic type pain -Either abnormal pancreas enzymes or duct dilation Type III -Pancreatic type pain only *Classic System includes delayed drainage >8 min

  43. Why Pancreatic SOD Classification is Not Useful • Few Type I pts reported, most IAP pts have normal PD caliber • IAP pts fit into Type II category and are primary pts of interest • Type III—an uncertain diagnosis

  44. Pancreatic SOD Therapy ChoicesWhat Type of Sphincterotomy? • Biliary ES: • Proposed as safer 1st step* • Dual purpose: treats microlithiasis and lowers panc SO pressure somewhat • Efficacy is only 28-50% • Higher failure rate than panc or dual ES *Levy AJG 2001

  45. Pancreatic SOD Therapy ChoicesWhat Type of Sphincterotomy? • Pancreatic ES alone • Treats correct portion of SO • Creates small biliary ES • Complete dual ES • Surgical sphincteroplasty • Insufficient data to support clear superiority for any method

  46. 65 yo woman, 3 episodes of IARP in one year

  47. Algorithm for IARP Idiopathic Acute Pancreatitis ↓ R/0 autoimmune / genetic pancreatitis ↓ EUS → diagnosis/treatment ↓ no diagnosis ERCP with manometry for >1 attack

  48. Pancreatic Endotherapy for Chronic Pancreatitis • Duct disruptions, pancreatic ascites • Pseudocyst drainage • Per ampulla-communicating cysts • Transluminal stents • Treatment of chronic pain • Stone clearance • Stricture treatment

  49. Stent for Duct Disruption • Resolution: 60-80% • Bridge disruption • Less success in AP

  50. Rules for Endoscopy of Pancreatic Pseudocysts • Symptomatic • True PP-not acute fluid collections (<4 wks) • EUS to assess wall (<10 mm) & R/O vessels • Antibiotic coverage • Surgical back-up

More Related